AxoGen (NASDAQ:AXGN) Price Target Raised to $50.00 at Citizens Jmp

AxoGen (NASDAQ:AXGN) had its target price boosted by Citizens Jmp from $42.00 to $50.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a market outperform rating on the medical equipment provider’s stock.

Other research analysts have also recently issued reports about the company. Wall Street Zen cut AxoGen from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Canaccord Genuity Group boosted their price target on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright boosted their price target on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research cut AxoGen from a “hold” rating to a “strong sell” rating in a report on Monday. Finally, Citigroup reissued an “outperform” rating on shares of AxoGen in a report on Wednesday. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.50.

AxoGen Stock Down 0.5%

AXGN stock opened at $41.77 on Wednesday. AxoGen has a twelve month low of $9.22 and a twelve month high of $45.83. The company has a quick ratio of 3.31, a current ratio of 5.11 and a debt-to-equity ratio of 0.51. The stock has a market cap of $2.17 billion, a P/E ratio of -122.85 and a beta of 0.98. The business’s 50-day moving average price is $33.49 and its 200-day moving average price is $30.29.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.04). AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%.The business had revenue of $61.46 million during the quarter, compared to analysts’ expectations of $57.85 million. On average, equities research analysts forecast that AxoGen will post -0.24 EPS for the current year.

Insider Transactions at AxoGen

In other AxoGen news, insider Erick Wayne Devinney sold 5,221 shares of AxoGen stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $32.84, for a total value of $171,457.64. Following the sale, the insider owned 262,781 shares of the company’s stock, valued at $8,629,728.04. The trade was a 1.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.78% of the stock is currently owned by insiders.

Institutional Trading of AxoGen

A number of large investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC increased its stake in AxoGen by 28.2% in the 3rd quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider’s stock worth $103,574,000 after acquiring an additional 1,276,487 shares during the last quarter. Vanguard Group Inc. increased its stake in AxoGen by 7.1% in the 4th quarter. Vanguard Group Inc. now owns 2,869,955 shares of the medical equipment provider’s stock worth $93,934,000 after acquiring an additional 190,557 shares during the last quarter. Morgan Stanley increased its stake in AxoGen by 6.5% in the 4th quarter. Morgan Stanley now owns 2,586,870 shares of the medical equipment provider’s stock worth $84,668,000 after acquiring an additional 157,029 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its stake in AxoGen by 20.4% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,958,406 shares of the medical equipment provider’s stock worth $34,938,000 after acquiring an additional 332,498 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its stake in AxoGen by 183.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock worth $20,953,000 after acquiring an additional 1,250,968 shares during the last quarter. Institutional investors own 80.29% of the company’s stock.

More AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Two analyst price-target raises lift sentiment — Citizens Jmp raised its target from $42 to $50 with a “market outperform” rating, and Wells Fargo raised its target from $40 to $48 with an “overweight” rating; both imply mid‑teens to ~20% upside from the current level. Benzinga Price Target Raises
• Positive Sentiment: Top-line beat: Q1 revenue of $61.46M topped consensus (~$57.8M), signaling continued demand growth for AxoGen’s peripheral nerve repair products despite margin pressure. AXGN Q1 2026 Earnings Call Highlights
• Neutral Sentiment: Full Q1 earnings materials and management commentary are available (earnings release, slide deck, and call/transcript), useful for digging into margin drivers and case volume trends. Q1 Slide Deck / Press Release
• Neutral Sentiment: Full earnings-call transcript and investor presentation posted for deeper read on product mix, reimbursement commentary, and international progress. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: EPS miss and margin pressure: reported EPS of $0.07 missed consensus (~$0.11–$0.12); management flagged rising expenses that pushed net margin negative, which is weighing on near‑term profitability expectations. Zacks: Q1 Earnings Lag Estimates
• Negative Sentiment: Analyst downgrade: Zacks moved AXGN from “hold” to “strong sell,” which could increase downside pressure from retail/quant strategies sensitive to rating changes. Zacks Research Downgrade
• Negative Sentiment: Guidance ambiguity: filings/notes indicate updates to FY‑2026 guidance but EPS guidance detail appears limited/unclear, leaving investors uncertain about FY profitability outlook. Press Release (GlobeNewswire)

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.